Does regular cannabis use affect neuroanatomy ? An updated systematic review and meta-analysis of structural neuroimaging studies Valentina Lorenzetti, Yann Chye, Pedro Silva, Nadia Solowij, Carl A. Roberts European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi : 10.1007/s00406-019-00979-1 Abstract Regular cannabis use is associated with adverse cognitive and mental health outcomes that have been ascribed to aberrant neuroanatomy in brain regions densely innervated with cannabinoid receptors. Neuroanatomical differences between cannabis users and controls have been assessed in multiple structural magnetic resonance imaging (sMRI) studies. However, there is heterogeneity in the results leading to cautious interpretation of the data so far. We examined the sMRI [...]
Lire la suiteBibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Dr Christian SUEUR, GRECC, novembre 2019. 2e version WORK in PROGRESS Il est à noter que, jusqu'aux années 2010, c'étaient les études et méta-analyses épidémiologiques qui "insistaient" sur la "dangerosité" du cannabis, en particulier sur les "pré" et jeunes adolescents, quant au risque de neurotoxicité, et vis à vis de la "production" de psychoses chroniques, liées à la consommation de cannabis cf mon article : Les méta-analyses et le cannabis, ou la négation du savoir clinique 21 Septembre 2011 Dr. Christian Sueur, Psychiatre, praticien hospitalier http://tdme.free.fr/?p=2730#annot8 https://www.grecc.org/publications/dossiers-scientifiques/les-meta-analyses-et-le-cannabis-ou-la-negation-du-savoir-clinique-21-sep-2011-dr-christian-sueur/ Aujourd'hui, on peut constater la raréfaction de ce type d'études épidémiologiques, qui étaient, [...]
Lire la suiteCannabinoid-Based Therapies and Brain Development : Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patrícia Schonhofen, Ivi Juliana Bristot, José Alexandre Crippa, Jaime Eduardo Cecílio Hallak, Antônio Waldo Zuardi, Richard B. Parsons, Fábio Klamt CNS Drugs, 2018, 32, (Suppl 1), 1-16. Springer Nature Switzerland, Doi : 10.1007/s40263-018-0550-4 Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor [...]
Lire la suitePrevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, 1, 133-138. Doi : 10.1089/can.2017.0006 Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]
Lire la suiteTransdermal Delivery of Cannabidiol Attenuates Binge Alcohol- Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder Daniel J. Liput, Dana C. Hammell, Audra L. Stinchcomb, and Kimberly Nixon Pharmacology, Biochemistry and Behavior, 2013, 111, 120–127. doi : 10.1016/j.pbb.2013.08.013 Abstract Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behavioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alcoholism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In experiment 1, 1.0%, 2.5% and 5.0% CBD gels were evaluated for neuroprotection. [...]
Lire la suiteChemistry, pharmacology and medicinal properties of Peganum harmala L. Jinous Asgarpanah and Fereshteh Ramezanloo African journal of pharmacy and pharmacology, 2012, 6, (22), 1573-1580. Doi : 10.5897/AJPP11.876 Peganum harmala L. is known as Syrian rue, Wild rue and Harmal. P. harmala extracts are considered important for drug development, because they are reported to have numerous pharmacological activities in the Middle East, especially in Iran and Egypt. For a long time P. harmala has been used in traditional medicines for the relief of pain and as an antiseptic agent. P. harmala also have antibacterial, antifungal, antiviral, antioxidant, antidiabetic, antitumor, antileishmanial, insecticidal and cytotoxic activities and hepatoprotective and antinociceptive effects. Harmaline, [...]
Lire la suiteDistribution, Status, Pharmacological, and Traditional importance of Peganum harmala L. Nissar Ahmad Khan, Aamir Raina, Nasir Aziz Wagay, Younas Rasheed Tantray International Journal of Advance research in Science and Engineering, 2017, 6, (8), 1887-1894. www.ijarse.com ABSTRACT Peganum harmala L. Commonly known as Syrian rue, Wild rue or Harmal is native to arid and semi-arid regions of Northern African and Asian deserts that have spread to parts of the southwestern United States and Northern Mexico. It is a multipurpose medicinal plant with antimicrobial, antifungal, anti inflammatory, antidiabetic, anti cancerous, hypothermic and hallucinogenic activities. Phytochemical investigations has revealed the presences of a number of active alkaloids [...]
Lire la suiteThe Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia David W. Volk and David A. Lewis Biological Psychiatry, 2016, 79, 595-603. http://dx.doi.org/10.1016/j.biopsych.2015.06.015 ABSTRACT Cannabis use has been reported to increase the risk of developing schizophrenia and to worsen symptoms of the illness. Both of these outcomes might be attributable to the disruption by cannabis of the endogenous cannabinoid system’s spatiotemporal regulation of the inhibitory circuitry in the prefrontal cortex that is essential for core cognitive processes, such as working memory, which are impaired in schizophrenia. In the healthy brain, the endocannabinoid 2-arachidonylglycerol 1) is synthesized by diacylglycerol lipase in pyramidal neurons; 2) [...]
Lire la suitePsychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]
Lire la suiteBibliographie : Substances psychédéliques et traitement des Addictions, Dr Christian Sueur, GRECC, novembre 2019 Ayahuasca, LSD, Kétamine, Psilocybine, Ibogaine, MDMA, Salvia divinorum et Mescaline, et traitement des Addictions
Lire la suite